Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Type 2 Diabetes and ADP Receptor Blocker Therapy.

Samoš M, Fedor M, Kovář F, Mokáň M, Bolek T, Galajda P, Kubisz P, Mokáň M.

J Diabetes Res. 2016;2016:6760710. doi: 10.1155/2016/6760710. Epub 2015 Dec 28. Review.

2.
3.

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM.

Postepy Kardiol Interwencyjnej. 2015;11(4):259-80. doi: 10.5114/pwki.2015.55596. Epub 2015 Jan 12. Review.

4.

A Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI].

Johnson TW, Mumford AD, Scott LJ, Mundell S, Butler M, Strange JW, Rogers CA, Reeves BC, Baumbach A.

PLoS One. 2015 Dec 16;10(12):e0144984. doi: 10.1371/journal.pone.0144984. eCollection 2015.

5.

Genes and Cardiovascular Disease: Where do we go from here?

Nadar SK, Sandhu K.

Sultan Qaboos Univ Med J. 2015 Nov;15(4):e448-51. doi: 10.18295/squmj.2015.15.04.001. Epub 2015 Nov 23. No abstract available.

6.

Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions.

Saab YB, Zeenny R, Ramadan WH.

Ther Clin Risk Manag. 2015 Sep 23;11:1421-7. doi: 10.2147/TCRM.S83293. eCollection 2015.

7.

Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Byrne RA, Joner M, Kastrati A.

Eur Heart J. 2015 Dec 14;36(47):3320-31. doi: 10.1093/eurheartj/ehv511. Epub 2015 Sep 28. Review.

8.

An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel.

Joo SJ, Choi JH, Kim SY, Kim KS, Kim YR, Kang SH.

Korean Circ J. 2015 Sep;45(5):378-85. doi: 10.4070/kcj.2015.45.5.378. Epub 2015 May 8.

9.

Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).

Liu Y, Liu H, Hao Z, Geng G, Chen Q, Han W, Jia K, Zhou Y.

Int J Clin Exp Med. 2015 Jul 15;8(7):11360-9. eCollection 2015.

10.

A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.

Lee JH, Ahn SG, Park B, Park SW, Kang YS, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Yoon J.

Korean J Intern Med. 2015 Sep;30(5):620-8. doi: 10.3904/kjim.2015.30.5.620. Epub 2015 Aug 27.

11.

Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial.

Li P, Yang Y, Chen T, Liu Y, Cao A, Liu J, Wang Z, Zhao X, Qin Y, Ma L.

Sci Rep. 2015 Sep 9;5:13789. doi: 10.1038/srep13789.

12.

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.

Geisler T, Booth J, Tavlaki E, Karathanos A, Müller K, Droppa M, Gawaz M, Yanez-Lopez M, Davidson SJ, Stables RH, Banya W, Zaman A, Flather M, Dalby M.

PLoS One. 2015 Aug 28;10(8):e0135037. doi: 10.1371/journal.pone.0135037. eCollection 2015.

13.

Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs.

Ford I.

Ther Adv Drug Saf. 2015 Aug;6(4):141-50. doi: 10.1177/2042098615588085. Review.

14.

Neurointerventional Stenting and Antiplatelet Function Testing: To Do or Not to Do?

Kass-Hout T, Alderazi YJ, Amuluru K, Jin P, Ayala C, Prestigiacomo C, Gandhi CD.

Interv Neurol. 2015 Jul;3(3-4):184-9. doi: 10.1159/000431261.

15.

Routine genotyping of patients on clopidogrel: Why the resistance?

Karthikeyan G.

Indian Heart J. 2015 Mar-Apr;67(2):93-4. doi: 10.1016/j.ihj.2015.04.008. Epub 2015 May 13. No abstract available.

16.

Genotype-based clinical trials in cardiovascular disease.

Pereira NL, Sargent DJ, Farkouh ME, Rihal CS.

Nat Rev Cardiol. 2015 Aug;12(8):475-87. doi: 10.1038/nrcardio.2015.64. Epub 2015 May 5. Review.

PMID:
25940926
17.

Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.

Jia M, Li Z, Chu H, Li L, Chen K.

Med Sci Monit. 2015 Apr 20;21:1131-7. doi: 10.12659/MSM.893914.

18.

State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK.

Curr Cardiovasc Risk Rep. 2015 Jan;9:4.

19.

Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).

Droppa M, Tschernow D, Müller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, Siller-Matula JM, Gawaz M, Geisler T.

PLoS One. 2015 Mar 23;10(3):e0121620. doi: 10.1371/journal.pone.0121620. eCollection 2015.

20.

Efficacy and safety of cangrelor for patients with coronary artery disease: a meta-analysis of four randomized trials.

Tang Y, Zhang YC, Chen Y, Xiang Y.

Int J Clin Exp Med. 2015 Jan 15;8(1):800-8. eCollection 2015.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk